Shire prunes San­fil­ip­po A drug af­ter a failed PhI­Ib

Shire is knock­ing one of its rare dis­ease drugs out of the pipeline. SHP610, once cit­ed in Flem­ming Orn­skov’s plan to swell rev­enue, is be­ing punt­ed af­ter the drug failed a Phase IIb for pa­tients with San­fil­ip­po A. The ther­a­py missed the pri­ma­ry end­point on im­prov­ing cog­ni­tion.

Shire’s shares $SH­PG dropped more than 3% this morn­ing, as an­a­lysts looked over a dis­ap­point­ing $386 mil­lion loss for Q3, which was worse than the mar­ket had reck­oned on.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.